Here's an example of what our custom alerts look like. Subscribers can monitor insider buying, stock splits, phase 3 trial updates, and more.
8-K filing released at 9:13 AM EST by PRSO Pharmaceuticals.
Paragraph 3 confirms Phase 3 trial for PRSO-102 met all primary endpoints with statistically significant results (p < 0.01).
Full text available on EDGAR: https://www.sec.gov/Archives/edgar/data/1234567/000123456721000123/0001234567-21-000123-index.htm
This alert was triggered by your "Phase 3 Trial Complete" catalyst setting.
This free sample is based on a real event: a company completing Phase 3 clinical trials and disclosing it in an 8-K. If you want alerts just like this — delivered to your inbox within minutes — sign up below.
Free tier includes this one alert type only. No credit card required.
You can upgrade to custom alerts anytime.